See more : Alphamin Resources Corp. (AFMJF) Income Statement Analysis – Financial Results
Complete financial analysis of Curative Biosciences, Inc. (CBDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Curative Biosciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Orient Paper & Industries Limited (ORIENTPPR.NS) Income Statement Analysis – Financial Results
- Al Rajhi Banking and Investment Corporation (1120.SR) Income Statement Analysis – Financial Results
- Conservative Broadcast Media & Journalism Inc. (CBMJ) Income Statement Analysis – Financial Results
- Johnson Electric Holdings Limited (JELCF) Income Statement Analysis – Financial Results
- NZX Limited (NZSTF) Income Statement Analysis – Financial Results
Curative Biosciences, Inc. (CBDX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://curativebio.com
About Curative Biosciences, Inc.
Curative Biosciences, Inc. focuses on developing and commercializing therapeutics using hemp-derived Cannabidiol. It intends to manufacture and market natural health products and operate in the medical cannabis industry. The company was formerly known as Amaize Beverage Corporation and changed its name to Curative Biosciences, Inc. in August 2017. Curative Biosciences, Inc. was founded in 2009 and is based in Miami, Florida.
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 2.85K | 2.85K |
| Gross Profit | -2.85K | -2.85K |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 0.00 | 50.00K |
| General & Administrative | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 50.35K | 1.59M |
| Other Expenses | 0.00 | 0.00 |
| Operating Expenses | 50.35K | 1.64M |
| Cost & Expenses | 53.20K | 1.64M |
| Interest Income | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 |
| Depreciation & Amortization | 2.85K | 2.85K |
| EBITDA | -50.35K | -1.65M |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -53.20K | -1.64M |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 0.00 |
| Income Before Tax | -53.20K | -1.66M |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | 2.00 | 3.00 |
| Net Income | -53.20K | -1.66M |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | 0.00 | -0.12 |
| EPS Diluted | 0.00 | -0.12 |
| Weighted Avg Shares Out | 15.71M | 13.93M |
| Weighted Avg Shares Out (Dil) | 15.71M | 13.93M |
Source: https://incomestatements.info
Category: Stock Reports